PMID- 34476725
OWN - NLM
STAT- MEDLINE
DCOM- 20220726
LR  - 20221207
IS  - 1863-4362 (Electronic)
IS  - 0021-1265 (Print)
IS  - 0021-1265 (Linking)
VI  - 191
IP  - 4
DP  - 2022 Aug
TI  - Sodium glucose co-transporter-2 inhibitor, Empagliflozin, is associated with 
      significant reduction in weight, body mass index, fasting glucose, and A1c levels 
      in Type 2 diabetic patients with established coronary heart disease: the SUPER 
      GATE study.
PG  - 1647-1652
LID - 10.1007/s11845-021-02761-6 [doi]
AB  - BACKGROUND: Empagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, 
      yielded significant beneficiaries in the treatment of type 2 diabetes mellitus 
      (T2DM). It is particularly benefited the diabetic subjects with heart conditions. 
      AIMS: We aimed to obtain a real-world data about the effects of empagliflozin 
      add-on treatment on metabolic parameters, cardiovascular risk factors, and 
      anthropometric measures in patients with T2DM. METHODS: Type 2 diabetic patients 
      with established coronary heart disease whom empagliflozin added to their 
      treatment were enrolled in the study. Anthropometric measures, clinical and 
      laboratory data, were obtained before and at the 6th month of the empagliflozin 
      treatment. All data before and at the 6th month were compared. RESULTS: Body 
      weight (p < 0.001), body mass index (p < 0.001), waist (p < 0.001) and hip 
      (p < 0.001) circumferences, systolic blood pressure (p = 0.006), heart rate 
      (p = 0.01), LDL cholesterol (p = 0.01), fasting plasma glucose (p < 0.001), and 
      HbA1c (p < 0.001) levels were significantly reduced on 6th month of empagliflozin 
      treatment compared to the baseline values. Estimated GFR (p = 0.66), serum 
      creatinine (p = 0.8), uric acid (p = 0.40), total cholesterol (p = 0.053), 
      triglyceride (p = 0.057), and HDL (p = 0.09) levels were not significantly 
      changed. CONCLUSIONS: We suggest that empagliflozin treatment may improve 
      anthropometric measures, metabolic parameters, and blood pressure and does not 
      cause deterioration in kidney functions in type 2 diabetic patients with 
      established coronary heart disease.
CI  - (c) 2021. Royal Academy of Medicine in Ireland.
FAU - Bilgin, Satilmis
AU  - Bilgin S
AD  - Abant Izzet, Baysal University Hospital , Department of Internal Medicine, Bolu, 
      Turkey.
FAU - Kurtkulagi, Ozge
AU  - Kurtkulagi O
AD  - Abant Izzet, Baysal University Hospital , Department of Internal Medicine, Bolu, 
      Turkey.
FAU - Duman, Tuba Taslamacioglu
AU  - Duman TT
AD  - Abant Izzet, Baysal University Hospital , Department of Internal Medicine, Bolu, 
      Turkey.
FAU - Tel, Burcin Meryem Atak
AU  - Tel BMA
AD  - Abant Izzet, Baysal University Hospital , Department of Internal Medicine, Bolu, 
      Turkey.
FAU - Kahveci, Gizem
AU  - Kahveci G
AD  - Abant Izzet, Baysal University Hospital , Department of Internal Medicine, Bolu, 
      Turkey.
FAU - Kiran, Murat
AU  - Kiran M
AD  - Abant Izzet, Baysal University Hospital , Department of Internal Medicine, Bolu, 
      Turkey.
FAU - Erge, Eray
AU  - Erge E
AD  - Abant Izzet, Baysal University Hospital , Department of Internal Medicine, Bolu, 
      Turkey.
FAU - Aktas, Gulali
AU  - Aktas G
AUID- ORCID: 0000-0001-7306-5233
AD  - Abant Izzet, Baysal University Hospital , Department of Internal Medicine, Bolu, 
      Turkey. draliaktas@yahoo.com.
LA  - eng
PT  - Journal Article
DEP - 20210902
PL  - Ireland
TA  - Ir J Med Sci
JT  - Irish journal of medical science
JID - 7806864
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sodium-Glucose Transporter 2 Inhibitors)
RN  - HDC1R2M35U (empagliflozin)
SB  - IM
MH  - Benzhydryl Compounds/therapeutic use
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - *Coronary Disease/complications/drug therapy
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Fasting
MH  - Glucosides/therapeutic use
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - *Hypoglycemic Agents/therapeutic use
MH  - *Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
MH  - Treatment Outcome
PMC - PMC8412859
OTO - NOTNLM
OT  - Coronary heart disease
OT  - Empagliflozin
OT  - Fasting glucose
OT  - HbA1c
OT  - Type 2 diabetes mellitus
COIS- The authors declare no competing interests.
EDAT- 2021/09/04 06:00
MHDA- 2022/07/27 06:00
PMCR- 2021/09/02
CRDT- 2021/09/03 07:05
PHST- 2021/08/14 00:00 [received]
PHST- 2021/08/25 00:00 [accepted]
PHST- 2021/09/04 06:00 [pubmed]
PHST- 2022/07/27 06:00 [medline]
PHST- 2021/09/03 07:05 [entrez]
PHST- 2021/09/02 00:00 [pmc-release]
AID - 10.1007/s11845-021-02761-6 [pii]
AID - 2761 [pii]
AID - 10.1007/s11845-021-02761-6 [doi]
PST - ppublish
SO  - Ir J Med Sci. 2022 Aug;191(4):1647-1652. doi: 10.1007/s11845-021-02761-6. Epub 
      2021 Sep 2.